AI-generated summary
The authors ran a triple blinded randomized trial of 221 head and neck cancer patients receiving chemoradiotherapy, comparing prophylactic low level laser therapy with sham treatment. They report that the laser group had significantly less severe oral mucositis, pain, dysphagia and opioid analgesic use. The abstract does not describe a long-term follow-up period.
- Participants
- 221
- Who or what was studied
- Head and neck cancer patients scheduled to undergo concurrent chemoradiotherapy with cisplatin
- Limits stated in the abstract
- The abstract does not describe long-term outcomes or report details of the blinding and randomization procedures beyond stating the design.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Power
- 24 mW
- Total energy
- 40 J
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Laser, Oral mucositis, Randomized controlled trial, Low-level laser therapy, Visual analogue scale, Sham. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.